188
Cancer Chemotherapy, Theoretical Foundations of
gene tumour mutation spectra,
Mutat. Res.
431
, 199–209.
Honma, T., Yoshizumi, T., Hashimoto, N., et al.
(2001) A novel approach for the development
of selective cdk4 inhibitors: library design
based on location of cdk4 speciFc amino acid
residues,
J. Med. Chem.
44
, 4628–4640.
Hostein, I., Robertson, D., DiStefano, ±., Work-
man, P.,
Clarke, P.A.
(2001) Inhibition
of
signal transduction by the Hsp90 inhibitor
17-allylamino-17-demethoxygeldanamycin re-
sults in cytostasis and apoptosis,
Cancer Res.
61
, 4003–4009.
Ivan, M., Kondo, K., Yang, H., et al. (2001) HI±
α
targeted for VHL-mediated destruction by
proline hydroxylation: implications for O
2
sensing,
Science
292
, 464–468.
Jaakkola, P., Mole, D.R., Tian, Y.M., et al. (2001)
Targeting of HI±-
α
to the von Hippel-Lindau
ubiquitylation complex by O
2
-regulated prolyl
hydroxylation,
Science
292
, 468–472.
Kantarjian,
H.
(2000)
Phase
II
study
of
ST1571,
a
tyrosine
kinase
inhibitor,
in
patients
with
resistant
or
refractory
Philadelphia chromosome positive chronic
myeloid leukaemia,
Blood
96
, 470a.
Ko,
L.,
Prives,
C.
(1996) p53:
puzzle
and
paradigm,
Genes Dev.
10
, 1054–1072.
Komarov, P.G., Komarova, E.A., Kondratov, R.V.,
et al. (1999) A chemical inhibitor of p53 that
protects mice from the side effects of cancer
therapy,
Science
285
, 1733–1737.
Kouzarides, T. (1999) Histone acetylases in cell
proliferation,
Curr. Opin. Genet. Dev.
9
,40–48.
Lando, D.,
Peet, D.J.,
Whelan, D.A.,
Gor-
man, J.J., Whitelaw, M.L. (2002) Asparagine
hydroxylation of the HI± transactivation do-
main: a hypoxic switch,
Science
295
, 858–861.
Laughner, E.,
Taghavi, P.,
Chiles, K.,
Ma-
hon, P.C., Semenza, G.L. (2001) HER2 (neu)
signalling
increases
the
rate
of
hypoxia-
inducible factor 1
α
(HI±1
α
) synthesis: novel
mechanism for HI±-1 mediated vascular en-
dothelial growth factor expression,
Mol. Cell.
Biol.
21
, 3995–4004.
Laurence, V., ±aivre, S., Vera, K., et al. (2002)
Preliminary results of an ongoing phase 1 and
pharmacokinetic study of CYC202, a novel oral
cyclin-dependent kinases inhibitor, in patients
with advanced malignancies,
Eur. J. Cancer
38
,
S49.
Li,Y.,Sun,X.,Lamout,J.T.,Pardee,A.B.,Li,C.J.
(2003) Selective killing of cancer cells by beta-
lapachone; direct checkpoint activation as a
strategy against cancer,
Proc. Natl. Acad. Sci.
U.S.A.
100
, 2674–2678.
Lin,
R.J.,
Nagy,
L.,
Inoue,
S.,
Shao,
W.,
Miller, W.H. Jr., Evans, R.M. (1998) Role
of
the
histone
deacetylase
complex
in
acute promyelocytic leukaemia,
Nature
391
,
811–814.
Manegold, C. (2003) GeFtinib (Iressa, ZD 1839)
for non-small cell lung cancer (NSCLC): recent
results and further strategies,
Adv. Exp. Med.
Biol.
532
, 247–252.
Mann,
M.J.,
Whittemore,
A.D.,
Donaldson,
M.D., et al. (2001) Ex-vivo gene therapy of
human vascular bypass grafts with E2± decoy:
the PREVENT single centre, randomised,
controlled trial,
Lancet
354
, 1493.
Marks, P.A., Rifkind, R.A., Richon, V.M., Bres-
low, R. (2001) Inhibitors of histone deacety-
lases
are
potentially
effective
anticancer
agents,
Clin. Cancer Res.
7
, 759–760.
McCarthy, M.
(2003) Anti-angiogenesis
drug
promising for metastatic colorectal cancer,
Lancet
361
, 1959.
McClue, S.J., Blake, D., Clarke, R., et al. (2002)
In vitro
and
in vivo
anti-tumour properties of
the cyclin-dependent kinase inhibitor CYC202
(R-Roscovitine),
Int. J. Cancer
102
, 463–468.
Montigiani, S.,
M¨uller, R.,
Kontermann, R.E.
(2003) Inhibition of cell proliferation and
induction of apoptosis by novel tetravalent
peptides inhibiting DNA binding of E2±,
Oncogene
22
, 4943–4952.
Moulder, S.L., Yakes, ±.M., Muthuswamy, S.K.,
Bianco, R., Simpson, J.±., Arteaga, C.L. (2001)
Epidermal growth factor receptor (HER1)
tyrosine kinase inhibitor ZD1839 (Iressa)
inhibits
HER2/
neu
(erbB2)-over-expressing
breast cancer cells
in vitro
and
in vivo
,
Cancer
Res.
61
, 8887–8895.
Nguyen, V.T.,
Kiss, T.,
Michels, A.A.,
Ben-
saude, O. et al. (2001) The 7SK small nuclear
RNA inhibits the CDK9/cyclinT1 kinase to
control transcription,
Nature
414
, 322–325.
Nimmanapalli, R., O’Bryan, E., Bhalla, K. (2001)
Geldanamycin and its analogue 17-allylamino-
17-demethoxygeldanamycin
lowers
Bcr-
Abl
levels
and
induces
apoptosis
and
differentiation
of
Bcr-Abl-positive
human
leukaemic blasts,
Cancer Res.
61
, 1799–1804.
Nix, D.,
Pien, C.,
Newman, R.,
et al.
(2001)
Clinical
development
of
a
proteasome
inhibitor, PS-341, for the treatment of cancer,
Proc. Am. Soc. Clin. Oncol.
20
, 86a.
previous page 862 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online next page 864 Encyclopedia of Molecular Cell Biology and Molecular Medicine read online Home Toggle text on/off